دورية أكاديمية
Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilms’ Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49)
| العنوان: | Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilms’ Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49) |
|---|---|
| المؤلفون: | Dorin Novacescu, Talida Georgiana Cut, Alin Adrian Cumpanas, Silviu Constantin Latcu, Razvan Bardan, Ovidiu Ferician, Cosmin-Ciprian Secasan, Andrei Rusmir, Marius Raica |
| المصدر: | Biomedicines, Vol 10, Iss 912, p 912 (2022) |
| بيانات النشر: | MDPI AG |
| سنة النشر: | 2022 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | adult renal cell carcinoma, Wilms’ tumor 1, WT1, clone WT49, immunohistochemistry, molecular pathology, Biology (General), QH301-705.5 |
| الوصف: | Renal cell carcinoma (RCC) is arguably the deadliest form of genitourinary malignancy and is nowadays viewed as a heterogeneous series of cancers, with the same origin but fundamentally different metabolisms and clinical behaviors. Immunohistochemistry (IHC) is increasingly necessary for RCC subtyping and definitive diagnosis. WT1 is a complex gene involved in carcinogenesis. To address reporting heterogeneity and WT1 IHC standardization, we used a recent N-terminus targeted monoclonal antibody (clone WT49) to evaluate WT1 protein expression in 56 adult RCC (aRCC) cases. This is the largest WT1 IHC investigation focusing exclusively on aRCCs and the first report on clone WT49 staining in aRCCs. We found seven (12.5%) positive cases, all clear cell RCCs, showing exclusively nuclear staining for WT1. We did not disregard cytoplasmic staining in any of the negative cases. Extratumoral fibroblasts, connecting tubules and intratumoral endothelial cells showed the same exclusively nuclear WT1 staining pattern. We reviewed WT1 expression patterns in aRCCs and the possible explanatory underlying metabolomics. For now, WT1 protein expression in aRCCs is insufficiently investigated, with significant discrepancies in the little data reported. Emerging WT1-targeted RCC immunotherapy will require adequate case selection and sustained efforts to standardize the quantification of tumor-associated antigens for aRCC and its many subtypes. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2227-9059 |
| العلاقة: | https://www.mdpi.com/2227-9059/10/4/912Test; https://doaj.org/toc/2227-9059Test; https://doaj.org/article/b5ee96349977485e8c37b673c71fcecaTest |
| DOI: | 10.3390/biomedicines10040912 |
| الإتاحة: | https://doi.org/10.3390/biomedicines10040912Test https://doaj.org/article/b5ee96349977485e8c37b673c71fcecaTest |
| رقم الانضمام: | edsbas.1061B7E7 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 22279059 |
|---|---|
| DOI: | 10.3390/biomedicines10040912 |